Search International and National Patent Collections
Refine Search
Query Tree
Save query
A private query is only visible to you when you are logged-in and can not be used in RSS feeds
Results 1-10 of 256 for Criteria:CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N) Office(s):all Language:en Stemming: false
Filters
1 2 3 4 5 6 7 8 9 10 11 12
Page: / 26
Analysis
List Length
TitleCtrPubDate
Appl.NoApplicantInventorInt.Class
NOVEL N-AMINOALKYL-1-BIPHENYLENYL-2-CARBOXAMIDES; NEW DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS
KR25.01.2000
1019980708238NEUROGEN CORPORATIONCHEN, XI
A61K 31/495
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

PURPOSE: A N-aminoalkyl-1-biphenylenyl-2-carboxamide being combined to a brain dopamine receptor subtype and a pharmaceutical composition including the compound are provided.

CONSTITUTION: Disclosed are compounds of formula (I) or the pharmaceutically acceptable acid addition salts thereof wherein: R1, R2, R3, R4, R5, R6 and R7 independently represent hydrogen, halogen, hydroxy, alkyl, alkoxy, amino, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, cyano, nitro, trifluoromethyl, or trifluoromethoxy; R8 is hydrogen or lower alkyl; X represents an optionally substituted alkylene group; and Y represents a mono- di- or tri-substituted cyclic amino group, which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which responds to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extra pyramidal side effects associated with the use of conventional neuroleptic agents.

COPYRIGHT 2000 KIPO


1-(ISOQUINOLIN-1-YL)-4-(1-PHENYLMETHYL)PIPERAZINES; DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS
KR26.12.2000
1019997007998NEUROGEN CORPORATIONCHEN XI
C07D 217/22
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
217
Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
22
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring

Disclosed are compounds useful in treating psychotic disorders such as schizophrenia and other central nervous system diseases, where the compounds have general Formula (I), wherein: Ar represents an aryl or heteroaryl group; R1and R2 independently represent hydrogen, halogen, C1-C6alkyl, C1- C4 alkoxy, C1-C4alkylthio, hydroxy, amino, mono- or di(C1-C6)alkyl amino, cyano or trifluoromethyl; and R5represents hydrogen or C1- C6alkyl.

© KIPO & WIPO 2007


N-AMINOALKYL-2-ANTHRAQUINONECARBOXAMIDES; NOVEL DOPAMINE RECEPTORS SUBTYPE SPECIFIC LIGANDS
KR25.01.2000
1019980708237NEUROGEN CORPORATIONJAN W. WASLEY, F.
A61K 31/495
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

PURPOSE: Novel compounds of formula I are provided which interact with dopamine receptor subtypes and are useful in the treatment and/or prevention of various neuropsychological disorders.

CONSTITUTION: The compounds of formula I and the pharmaceutically acceptable acid addition salts thereof may be prepared by the reaction shown below in scheme 1, wherein a compound of formula V is activated by treating the acid V with an activating agent such as refluxing thionyl chloride(SOCl2)or the like. The resulting activated species, e.g., an acyl chloride, may be subsequently reacted with the required compound of formula VI at room temperature, optionally in a suitable solvent such as chloroform, to afford a compound of formula I as the desired product.

COPYRIGHT 2000 KIPO


THREE MEMBERED RING AMINOAKYLCARBOXAMIDE, NOVEL DOPAMINE D3 RECEPTOR SUB-TYPE SPECIFIC RIGAND
KR15.02.2000
1019980708491NEUROGEN CORPORATIONCHEN JAI
C07D 221/10
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
221
Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/-C07D219/187
02
condensed with carbocyclic rings or ring systems
04
Ortho- or peri-condensed ring systems
06
Ring systems of three rings
10
Aza-phenanthrenes

PURPOSE: Selective D3 antagonist can be used for an effective anti-mental disease medicine without having neurological side effects used to be common from nerve relaxing agent.

CONSTITUTION: Aminocarboxamide having three-membered ring is represented by formula I wherein R1 and R2 is the same or different, H, C1-C6-alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C1-C6-alkoxy, -O2CR', -NGCOR', -XOmR'(wherein R' is C1-C6 alkyl and m is 0, 1, or 2); or R1 and R2 are -CONR'R" or -NR'R"(wherein R' and R" are H or C1-C6-alkyl independently); R3 is H or lower alkyl; A is C1-C4 substituted with one or more alkyl or C2-C6-alkylene without substitution; Y is methylene, O, sulfur, or NH; X is N, C, CH.

COPYRIGHT 2000 KIPO


3-ARYL SUBSTITUTED PYRAZOLO[4,3-d]PYRIMIDINEDERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF1) SPECIFIC LIGANDS
KR25.11.2000
1019997005989NEUROGEN CORPORATIONYUAN JUN
C07D 487/04
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems

This invention encompasses compounds of formula (I), wherein Ar represents a mono-, di- or trisubstituted aryl group where at least one position on Ar ortho to the point of attachment to the pyrazole ring is substituted; and R1represents lower alkyl; R2is hydrogen or lower alkyl; and R3and R4 independently represent organic and inorganic substituents, which compounds are highly selective partial agonists or antagonists at human CRF1receptors and are useful in the diagnosis and treatment of treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety.

© KIPO & WIPO 2007


METHODS FOR PREVENTING AND TREATING OBESITY IN PATIENTS WITH MC4 RECEPTOR MUTATIONS
WO08.04.2004
PCT/US2003/029916NEUROGEN CORPORATIONRAJACHANDRAN, Lavanya
A61K 31/00
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
Methods are provided for treating health conditions associated with altered MC4 receptor activity with melanin concentrating hormone receptor antagonists. Such compounds may be used, for example, to treat or prevent obesity and/or overeating, and to reduce body mass index, in patients carrying one or more MC4 receptor mutations.

4-SUBSTITUTED QUINOLINE DERIVATIVES AS GABA RECEPTOR LIGANDS
WO05.10.2000
PCT/US2000/008196NEUROGEN CORPORATIONYUAN, Jun
C07D 401/04
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
Disclosed are compounds of the Formula (I) where R1, R2, R3, R4, X, Y1 and Y2 are defined herein. These compounds bind with high affinity to GABAA receptors. Also disclosed are pharmaceutical compositions comprising these compounds, and methods of treating patients suffering from certain central nervous system and peripheral diseases or disorders with these pharmaceutical compositions. This invention also relates to the use of such compounds in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. The compounds of this invention are also useful as probes for the localization of GABAA receptors.

1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4)
KR25.11.2000
1019997006894NEUROGEN CORPORATIONCHEN XI
C07D 295/06
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
295
Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
04
with substituted hydrocarbon radicals attached to ring nitrogen atoms
06
substituted by halogen atoms or nitro radicals

Disclosed are compounds of formula (I) or the pharmaceutically acceptable addition salts thereof wherein: R 1 is halogen or C 1 -C 4 alkyl; and R 2 and R 3 are the same or different and represent hydrogen, halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, alkylthio, hydroxy, amino, mono(C 1 -C 4)alkylamino, di(C 1 -C 4)alkylamino, or R 2 and R 3 together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are dopamine D4(ant)agonists and useful in the treatment of neuropsychological diseases such as schizophrenia, psychotic depression and mania.

© KIPO & WIPO 2007


CERTAIN SUBSTITUTED BENZYLAMINE DERIVATIVES; A NEW CLASS OF NEUROPEPTIDE-Y1 SPECIFIC LIGANDS
WO29.01.1998
PCT/US1997/012616NEUROGEN CORPORATIONBLUM, Charles, A.
C07D 211/46
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
211
Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
04
with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
06
having no double bonds between ring members or between ring members and non-ring members
36
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
40
Oxygen atoms
44
attached in position 4
46
having a hydrogen atom as the second substituent in position 4
This invention encompasses compounds of formula (I) and the pharmaceutically acceptable salts thereof, wherein X1, X2, X3 represent organic or inorganic susbtituents, n is 1, 2, or 3, R1-R4 are hydrogen or organic substituents, and B is nitrogen, carbon, sulfur or oxygen, useful in the diagnosis and treatment of feeding disorders such as obesity and bulimia and cardiovascular diseases such as essential hypertension and congestive heart failure due to the binding of these compounds to human Neuropeptide Y1 receptors.

NOVEL N-AMINOALKYL-2-ANTHRACENECARBOXAMIDES; NEW DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS
WO25.09.1997
PCT/US1997/004418NEUROGEN CORPORATIONYUAN, Jun
C07D 211/14
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
211
Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
04
with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
06
having no double bonds between ring members or between ring members and non-ring members
08
with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
10
with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
14
with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
Disclosed are compounds of formula (I), or the pharmaceutically acceptable acid addition salts thereof, wherein: R1, R2, R3, R4, R5, R6, R7, R8 and R9 are the same or different and represent hydrogen, C1-C6 alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C1-C6 alkoxy, -O2CR', -NHCOR', COR', -SOmR', where R' is C1-C6 alkyl and wherein m is 0, 1 or 2; or R1, R2, R3, R4, R5, R6, R7, R8 and R9 independently represent -CONR'R'', or -NR'R'' where R' and R'' independently represent hydrogen or C1-C6 alkyl; R10 is hydrogen or C1-C6 alkyl; and R represents an aminoalkyl group; which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.

Results 1-10 of 256 for Criteria:CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N) Office(s):all Language:en Stemming: false
Filters
1 2 3 4 5 6 7 8 9 10 11 12
Page: / 26